Delineation of antigen-specific and antigen-nonspecific CD8 (cid:1) memory T-cell responses after cytokine-based cancer immunotherapy

Memory T cells exhibit tremendous antigen specificity within the immune system and accumulate with age. Our studies reveal an antigen-independent expansion of memory, but not naive, CD8 (cid:1) T cells after several immunotherapeutic regimens for cancer resulting in a distinctive phenotype. Signaling through T-cell receptors (TCRs) or CD3 in both mouse and human memory CD8 (cid:1) T cells markedly up-regulated programmed death-1 (PD-1) and CD25 (IL-2 receptor (cid:2) chain), and led to antigen-specific tumor cell killing. In contrast, exposure to cytokine alone in vitro or with immunotherapy in vivo did not up-regulate these markers but resulted in expanded memory CD8 (cid:1) T cells expressing NKG2D, granzyme B, and pos-sessing broadly lytic capabilities. Blockade of NKG2D in mice also resulted in significantly diminished antitumor effects after immunotherapy. Treatment of TCR-transgenic mice bearing nonantigen expressing tumors with immunotherapy still resulted in significant antitumor effects. Human melanoma tissue biopsies obtained from patients after topically applied immunodulatory treatment resulted in increased numbers of these CD8 (cid:1) CD25 (cid:3) cells within the tumor site. These findings demonstrate that memory CD8 (cid:1) T cells can express differential phenotypes indicative of adaptive or innate effectors based on the nature of the stimuli in a process conserved across species. up-regulation also occurred after cells were cultured in IL-2 (Figure 2D). These results indicate that cytokine-based stimulation results in a markedly different phenotype on the memory CD8 (cid:1) T-cell population.

[1]  X. Zang,et al.  The PD-1/PD-L1 (B7-H1) Pathway in Chronic Infection-Induced Cytotoxic T Lymphocyte Exhaustion , 2011, Journal of biomedicine & biotechnology.

[2]  D. Munn,et al.  Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. , 2010, Blood.

[3]  G. Freeman,et al.  Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection , 2010, Proceedings of the National Academy of Sciences.

[4]  S. Jonjić,et al.  Intact NKG2D-Independent Function of NK Cells Chronically Stimulated with the NKG2D Ligand Rae-1 , 2010, The Journal of Immunology.

[5]  S. Rosenberg,et al.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. , 2009, Blood.

[6]  A. Fauci,et al.  The Common γ-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands , 2008, The Journal of Immunology.

[7]  N. Greenberg,et al.  NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. , 2008, Immunity.

[8]  J. Weiss,et al.  Regulatory and Conventional CD4+ T Cells Show Differential Effects Correlating with PD-1 and B7-H1 Expression after Immunotherapy12 , 2008, The Journal of Immunology.

[9]  Lloyd J. Old,et al.  Adaptive immunity maintains occult cancer in an equilibrium state , 2007, Nature.

[10]  J. Weiss,et al.  IFN-γ mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy , 2007, Nature Medicine.

[11]  T. Sayers,et al.  NK Cells Use NKG2D to Recognize a Mouse Renal Cancer (Renca), yet Require Intercellular Adhesion Molecule-1 Expression on the Tumor Cells for Optimal Perforin-Dependent Effector Function1 , 2006, The Journal of Immunology.

[12]  T. Kozel,et al.  Immunomodulation with CD40 Stimulation and Interleukin-2 Protects Mice from Disseminated Cryptococcosis , 2006, Infection and Immunity.

[13]  L. Lanier,et al.  NKG2D in NK and T Cell-Mediated Immunity , 2005, Journal of Clinical Immunology.

[14]  Eric J. Brown,et al.  The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor , 2005, Nature.

[15]  Salim Dhanji,et al.  Self-reactive memory-phenotype CD8 T cells exhibit both MHC-restricted and non-MHC-restricted cytotoxicity: a role for the T-cell receptor and natural killer cell receptors. , 2004, Blood.

[16]  Robert S Negrin,et al.  Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. , 2004, Blood.

[17]  K. Sheppard,et al.  PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. , 2004, FEBS letters.

[18]  J. Forman,et al.  Memory CD8+ T Cells Provide Innate Immune Protection against Listeria monocytogenes in the Absence of Cognate Antigen , 2003, The Journal of experimental medicine.

[19]  Salim Dhanji,et al.  IL-2-Activated CD8+CD44high Cells Express Both Adaptive and Innate Immune System Receptors and Demonstrate Specificity for Syngeneic Tumor Cells 1 , 2003, The Journal of Immunology.

[20]  J. Wigginton,et al.  Synergistic Anti-Tumor Responses After Administration of Agonistic Antibodies to CD40 and IL-2: Coordination of Dendritic and CD8+ Cell Responses 1 , 2003, The Journal of Immunology.

[21]  A. Diefenbach,et al.  A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity , 2003, European journal of immunology.

[22]  I. Wang,et al.  Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 Responses , 2003, The Journal of Immunology.

[23]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Wigginton,et al.  IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside , 2002, Expert opinion on biological therapy.

[25]  G. Freeman,et al.  PD‐1:PD‐L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL‐2 , 2002, European journal of immunology.

[26]  Y. Kawarada,et al.  NK- and CD8+ T Cell-Mediated Eradication of Established Tumors by Peritumoral Injection of CpG-Containing Oligodeoxynucleotides1 , 2001, The Journal of Immunology.

[27]  A. Diefenbach,et al.  Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity , 2001, Nature.

[28]  P. Doherty,et al.  Virus-Specific and Bystander CD8+T-Cell Proliferation in the Acute and Persistent Phases of a Gammaherpesvirus Infection , 2001, Journal of Virology.

[29]  C. Hunter,et al.  Bystander Activation of CD8+ T Cells Contributes to the Rapid Production of IFN-γ in Response to Bacterial Pathogens1 , 2001, The Journal of Immunology.

[30]  S. Riddell,et al.  Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. , 2001, Nature immunology.

[31]  P. Marrack,et al.  Control of homeostasis of CD8+ memory T cells by opposing cytokines. , 2000, Science.

[32]  C. Kurts,et al.  Characterization of the ovalbumin‐specific TCR transgenic line OT‐I: MHC elements for positive and negative selection , 2000, Immunology and cell biology.

[33]  J. Sprent,et al.  T-cell proliferation in vivo and the role of cytokines. , 2000, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[34]  A Steinle,et al.  Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. , 1999, Science.

[35]  H. Eisen,et al.  Functional differences between memory and naive CD8 T cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Sprent,et al.  T-cell turnover in vivo and the role of cytokines. , 1999, Immunology letters.

[37]  J. Sprent,et al.  Bystander stimulation of T cells in vivo by cytokines. , 1998, Veterinary immunology and immunopathology.

[38]  J. Altman,et al.  Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. , 1998, Immunity.

[39]  J. Altman,et al.  In vivo dynamics of anti-viral CD8 T cell responses to different epitopes. An evaluation of bystander activation in primary and secondary responses to viral infection. , 1998, Advances in experimental medicine and biology.

[40]  R. Welsh,et al.  Minimal Bystander Activation of CD8 T Cells during the Virus-induced Polyclonal T Cell Response , 1997, The Journal of experimental medicine.

[41]  R. Zinkernagel,et al.  Bystander Activation of Cytotoxic T Cells: Studies on the Mechanism and Evaluation of In Vivo Significance in a Transgenic Mouse Model , 1997, The Journal of experimental medicine.

[42]  J. Sprent,et al.  Induction of Bystander T Cell Proliferation by Viruses and Type I Interferon in Vivo , 1996, Science.

[43]  T. Honjo,et al.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. , 1996, International immunology.

[44]  J. Sprent,et al.  Viruses and T Cell Turnover: Evidence for Bystander Proliferation , 1996, Immunological reviews.

[45]  H. Pircher,et al.  Visualization, characterization, and turnover of CD8+ memory T cells in virus-infected hosts , 1996, The Journal of experimental medicine.

[46]  J. Franco,et al.  Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. , 1996, Journal of the National Cancer Institute.

[47]  P. Doherty,et al.  Recruitment and proliferation of CD8+ T cells in respiratory virus infections. , 1995, Journal of immunology.